| 1 |
31405143 | ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. | 2019 Aug 10 |
3 |
| 2 |
28521419 | Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma. | 2017 May |
2 |
| 3 |
23482788 | Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. | 2013 Mar |
1 |
| 4 |
21289518 | Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors. | 2011 Mar |
2 |
| 5 |
19683826 | The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. | 2010 Jun |
1 |
| 6 |
20047843 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. | 2010 Sep |
1 |
| 7 |
20443070 | Impact of biomarkers on non-small cell lung cancer treatment. | 2010 Mar |
2 |
| 8 |
22993560 | Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane. | 2010 May |
1 |
| 9 |
18395930 | Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. | 2008 Oct |
1 |